 B.I.0101 is a CAR-T cell. It was designed by researchers from Hadassah, Professor Poulin-Estepansky and Bar-Ilan University. This is White's H.B.I. And it's locally produced CAR-T cells. Now the advantage was that we can design and work at our own hospital and give it to our patients where CAR-T is not available in most countries, especially in Israel right now. So CAR-T is a technology where you take the patient's T-cells, which are lymphocytes that know to kill other cells, but they don't recognize the patient's plasma cells that are aviodogenic or making the myeloma. And you insert into the lymphocytes, you insert a construct that recognizes the plasma cells and attaches to them, then the lymphocytes are going to the plasma cells and are killing them. And responses are phenomenal. So the patient, most patients will respond. The main problem is that in the first week of treatment, you get severe side effects. We have the whole immune system that is overworking. And patients have high fever, low blood pressure, shortness of breath. So when you're speaking about the amyloidosis patients, these patients are usually, especially if they have a heart involvement, they are very vulnerable for aggressive therapy. And so nobody in the world would want really to do a CAR-T cell trial for amyloidosis patients. And so this is the advantage of what we did. So we're the first in the world that are allowing amyloidosis patients to receive CAR-T cells in a clinical trial. And we had very favorable results. So patients are responding very well. And it's actually safe. Patients do the procedure, most of them, even if they do have some sort of organ deterioration, kind of a little bit of heart failure or kidney failure. It is transient. It's manageable. And most of them will do it and feel much, much better. And the responses are very high. So most patients are responding. And not only they are responding, they go into very deep remission, which is very important in amyloidosis because in amyloidosis it's been proven again and again that the light chains are toxic to the organs, to the heart, to the kidneys, to whatever organs involved. So if you are able to reduce the light chains to zero, and this is what the CAR-T or any immunotherapy nowadays does, they reduce the light chains to zero, not normal zero. So you don't have amyloidosis anymore. You don't have the toxic light chains anymore. And patients get better fast. So they really feel much, much faster. The shortness of breath goes away. The proteinuria, if they have renal involvement, is relatively fast decreasing. So it's a very promising therapy. And the most important thing is to show the world that it's feasible, that you can do it to amyloidosis patients because usually amyloidosis patients are not included in clinical trials because nobody, everybody is afraid of them. They're so frail and so fragile. Most of the patients were very advanced patients and we still are, accepting patients who are after a few lines of therapy, it's not newly diagnosed or even second or third line patients, it's for patients who are relapsing again and again. And so the patients are very difficult patients or let's say the most difficult patients there are. After many, many lines of therapy, some of them. And therefore the ability, while most therapies that we have are giving partial responses, even those that give better responses, they usually are not able to give us that big responses to repress these malignant plasma cells. So first of all, as I said, it's the most important thing is that it's safe. So people would be able to do it, not just in Israel, while CAR T therapy is in some countries available for myeloma patients and but most physicians will not dare to give it to their amyloidosis patients. So now they see that it's feasible that they can do it and it's not that unsafe, it's you can manage side effects. And so that's the most important thing. And obviously showing that most patients again, we have 100% response rate. All patients, we haven't done that many patients, we've done 11 patients by now, but they all are responding. And some of them for a short time because they're really very severe patients, but most of them are responding and have a deep responses. And one advantage that we hope may be a long time to see, it's too early to say, but that actually amyloidosis patients may fare better than myeloma patients because they don't have a large load of disease like myeloma patients. So in myeloma patients, their ability is an issue. We'll see if myeloma patients will do even better.